secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azenta, Inc. (AZTA)
CIK:        0000933974
Form:       8-K
Filed at:   2024-02-07T23:59:59+00:00
Accession:  0001558370-24-000860
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azenta Q1 rev $154M (-13% YoY), GAAP EPS ($0.28), non-GAAP $0.02; reaffirms FY24 guide
--------------------------------------------------------------------------------

- Revenue $154M, down 13% YoY; organic revenue -15%; combined Sample Mgmt & Multiomics grew 2% organic.
- GAAP diluted EPS from continuing ops ($0.28) vs ($0.15) prior year; non-GAAP diluted EPS $0.02 vs $0.12.
- B Medical revenue $13M, down 70% YoY (timing of orders); Sample Mgmt Solutions up 5%, Multiomics up 3%.
- FY2024 guidance reaffirmed: total revenue $696-$718M, non-GAAP EPS $0.19-$0.29, adj EBITDA margin +300bps.
- Repurchased 2.3M shares for $113M in Q1; plans additional $500M in FY2024 to complete $1.5B authorization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/933974/000155837024000860/0001558370-24-000860-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/933974/000155837024000860/azta-20240207x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-000860

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer